Celularity Inc.: financial statements

CELUNASDAQHealthcare · Pharmaceutical Preparations

Price

$0.62

November 16, 2026Market cap $20M

What Ploutos Investor adds for Celularity

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 51% since Oct 20, 2026, when the 10-Q these figures come from was filed ($1.26 then, $0.62 on Nov 16, 2026). The figures date from before that move.10-Q
  • A figure that did not match the numbers it is built from has been left out.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+8.0% a year over 2 years

Line202320242025Average a year
Revenue $23M$54M$27M+8.0%
Cost of revenue $16M$15M$20M+11.9%
Gross profit $6.8M$39M$6.5M-2.1%
Operating income -$192M-$38M-$61M
Net income -$196M-$58M-$92M
Earnings per share -$11.02-$2.64-$3.59
Earnings per share, basic -$11.02-$2.64-$3.59
Margins
Gross margin 29.7%72.4%24.4%
Operating margin -844.4%-70.7%-230.9%
Net margin -862.0%-106.8%-345.4%

Financial statements

CELU's revenue, profits and cash flows from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: Degenerative Disease $17M, Biobanking $5.4M, Cell Therapy –
  • 2024: Degenerative Disease $48M, Biobanking $5.1M, Cell Therapy $688.0K
  • 2025: Degenerative Disease $17M, Biobanking $5.4M, Cell Therapy $3.8M
Segment202320242025Share 2025
Degenerative Disease$17M$48M$17M65%
Biobanking$5.4M$5.1M$5.4M20%
Cell Therapy–$688.0K$3.8M14%

By segment

CELU's revenue by segment from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$27M Leases0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$27M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Goodwill by segment

Dec 31, 2025

Total goodwill

$7.3M

  • Biobanking$7.3M100%

Goodwill is what the company paid in acquisitions above the value of what it bought, at December 31, 2025. If an acquisition earns less, the goodwill is impaired and earnings fall. The filing

$7.3MTotal goodwill

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-19.0 pts

Difference the filing does not itemize

-2.0 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Taxes: deferred and paid

The deferred part was 100.0% of the tax charge in the year to Dec 31, 2025.

  • The deferred share is higher than at nine in ten S&P 500 companies.
Deferred share, year to Dec 31, 2025$3.0K of $3.0K
100.0%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: a figure it needs is missing from the company's structured filings.

Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Celularity's filings show?

These are Celularity's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CELU's financials

Didn't find what you were looking for?

Ask us
How much revenue did CELU have in 2025?

Celularity had revenue of $27M and net income of -$92M in fiscal 2025, a net margin of -345.4%.

How much debt does CELU have?

On December 31, 2025 Celularity had total assets of $107M, debt of $34M and shareholders' equity of -$38M.

Where are the figures from?

From Celularity Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.